TNGX Tango Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1819133 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY121.5%
TTM net income YoY15.0%
TTM EPS YoY36.4%
Revenue 3-yr CAGR16.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-253.4%
Net margin-229.9%
FCF margin-268.1%
EBITDA margin-249.8%
Returns
ROE-21.3%
ROA-18.9%
ROIC (approx.)-28.5%
Asset turnover0.08x
Leverage & solvency
Liabilities / assets4.6%
Debt / equity0.00x
Current ratio50.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.16x
Accruals ratio3.1%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $53.81M | $3.18M | $5.39M | $4.12M |
| R&D expense | $48.93M | $37.20M | $33.53M | $32.10M | $30.82M | $32.81M | $36.44M | $33.94M |
| SG&A expense | $29.19M | $22.59M | $15.23M | $9.76M | $8.92M | $11.34M | $11.48M | $11.09M |
| Operating income | -$78.12M | -$59.78M | -$48.77M | -$41.86M | $14.07M | -$40.97M | -$42.53M | -$40.91M |
| Pretax income | -$68.39M | -$55.34M | -$45.51M | -$38.80M | $15.87M | -$38.82M | -$39.84M | -$37.62M |
| Income tax | $0 | $1,000 | $1,000 | -$55,000 | -$10,000 | $35,000 | $34,000 | $49,000 |
| Net income | -$68.39M | -$55.34M | -$45.51M | -$38.75M | $15.88M | -$38.85M | -$39.88M | -$37.67M |
| EBITDA | -$77.70M | -$59.36M | -$48.31M | -$41.38M | $14.63M | -$40.34M | -$41.91M | -$40.29M |
| EPS (basic) | -0.39 | -0.37 | -0.32 | — | 0.14 | -0.35 | -0.36 | — |
| EPS (diluted) | -0.39 | -0.37 | -0.32 | — | 0.13 | -0.35 | -0.36 | — |
| Weighted avg. shares (diluted) | 173.93M | 149.88M | 143.58M | — | 117.78M | 110.54M | 110.30M | — |
| Banking | ||||||||
| Net interest income | $7.15M | $3.72M | $2.18M | $1.68M | $1.10M | $1.24M | $1.61M | $1.81M |
| Balance sheet | ||||||||
| Cash & equivalents | $86.83M | $345.56M | $157.83M | $112.28M | $58.34M | $58.34M | $58.43M | $69.53M |
| Short-term investments | $890.67M | $668.43M | $222.01M | $230.86M | $94.47M | $141.51M | $158.29M | $188.39M |
| Current assets | $992.66M | $1.03B | $392.33M | $353.76M | $163.78M | $190.10M | $224.93M | $266.34M |
| PP&E, net | $5.75M | $6.09M | $6.38M | $6.87M | $7.35M | $7.79M | $7.54M | $8.10M |
| Total assets | $1.03B | $1.07B | $435.79M | $398.69M | $210.14M | $237.89M | $274.31M | $316.49M |
| Current liabilities | $25.16M | $20.30M | $14.33M | $21.68M | $18.44M | $40.02M | $35.92M | $38.17M |
| Total liabilities | $53.29M | $49.35M | $44.29M | $52.51M | $50.10M | $102.94M | $107.55M | $116.97M |
| Shareholders' equity | $980.17M | $1.02B | $391.51M | $346.18M | $160.03M | $134.95M | $166.76M | $199.52M |
| Shares outstanding | 169.21M | 168.38M | 144.16M | 135.94M | 111.57M | 110.87M | 108.11M | 107.73M |
| Cash flow statement | ||||||||
| Operating cash flow | -$37.14M | -$38.87M | -$44.36M | -$29.72M | -$30.95M | -$36.52M | -$41.70M | -$36.65M |
| Capital expenditure | $77,000 | -$20,000 | -$2,000 | $222,000 | $151,000 | $624,000 | $51,000 | $124,000 |
| Free cash flow | -$37.22M | -$38.85M | -$44.36M | -$29.94M | -$31.10M | -$37.14M | -$41.75M | -$36.77M |
| Investing cash flow | -$223.98M | -$445.97M | $9.63M | -$135.72M | $47.48M | $16.78M | $30.60M | $52.06M |
| Financing cash flow | $2.40M | $672.57M | $79.85M | $219.38M | $2.54M | $581,000 | $2,000 | $969,000 |
| Depreciation & amortization | $420,000 | $425,000 | $463,000 | $479,000 | $555,000 | $625,000 | $622,000 | $620,000 |
| Stock-based compensation | $24.91M | $16.89M | $10.80M | $5.98M | $6.62M | $6.57M | $7.25M | $7.46M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.